GoAI
Get started
JD Health International Inc. logo

JD Health International Inc.

6618.HK

HKSEHealthcareMedical - Pharmaceuticals

Open in GoAI

Latest quote

HK$37.32

−HK$1.34 · -3.47%

Aug 24, 11:55 AM HKT

6618.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as over-the-counter and prescription medications, medical devices, and health supplements. These goods are distributed through both direct sales and an extensive online retail pharmacy network. Beyond product offerings, its comprehensive service suite includes virtual medical consultations, patient referrals to hospitals and doctors, health screening programs, genetic testing, and beauty care services. Additionally, it develops intelligent healthcare and wellness management solutions, alongside providing technical support and advertising services. The platform also facilitates access to various medical provisions, including general health examinations, cosmetic medical procedures, vaccination bookings, dental treatments, and nucleic acid testing. Incorporated in 2018 and headquartered in Beijing, People's Republic of China, JD Health International Inc. is a subsidiary of JD Jiankang Limited.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
CN
CEO
Cao Dong
Listed since
Dec 8, 2020
Employees
5,263

Market position

Volume
4.29M
0.42× average
Average volume
10.16M
Average daily volume
Market cap
119.84B HKD
Beta
1.18
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
128.16B CNY
P/E (TTM)
16.66×
P/B (TTM)
1.65×
P/S (TTM)
1.31×
EV / EBITDA
32.24×
Earnings yield
3.37%
Free cash flow yield
6.12%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
25.29%
Operating margin
6.10%
Net margin
7.86%
Return on equity
8.94%
Return on assets
6.59%
Return on invested capital
5.53%

Financial health

Debt / equity
0.01×
Current ratio
2.72×
Altman Z-score
5.23
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends28%16%4%-8%Gross margin, FY2021: 23.46%Gross margin, FY2022: 21.16%Gross margin, FY2023: 22.17%Gross margin, FY2024: 22.88%Gross margin, FY2025: 24.78%Operating margin, FY2021: -4.58%Operating margin, FY2022: -0.31%Operating margin, FY2023: 1.31%Operating margin, FY2024: 2.00%Operating margin, FY2025: 5.17%Net margin, FY2021: -3.50%Net margin, FY2022: 0.81%Net margin, FY2023: 4.00%Net margin, FY2024: 7.16%Net margin, FY2025: 7.32%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 23.46%. Gross margin FY2022 21.16%. Gross margin FY2023 22.17%. Gross margin FY2024 22.88%. Gross margin FY2025 24.78%. Operating margin FY2021 -4.58%. Operating margin FY2022 -0.31%. Operating margin FY2023 1.31%. Operating margin FY2024 2.00%. Operating margin FY2025 5.17%. Net margin FY2021 -3.50%. Net margin FY2022 0.81%. Net margin FY2023 4.00%. Net margin FY2024 7.16%. Net margin FY2025 7.32%.

Income trends

Revenue

73.44B CNY+26.28%

Operating income

3.8B CNY+226.59%

Net income

5.38B CNY+29.16%
Income trends across reported periods80.93B CNY50.99B CNY21.05B CNY−8.89B CNYRevenue, FY2021: 30.68B CNYRevenue, FY2022: 46.74B CNYRevenue, FY2023: 53.53B CNYRevenue, FY2024: 58.16B CNYRevenue, FY2025: 73.44B CNYOperating income, FY2021: −1.4B CNYOperating income, FY2022: −145.12M CNYOperating income, FY2023: 700.71M CNYOperating income, FY2024: 1.16B CNYOperating income, FY2025: 3.8B CNYNet income, FY2021: −1.07B CNYNet income, FY2022: 380.11M CNYNet income, FY2023: 2.14B CNYNet income, FY2024: 4.16B CNYNet income, FY2025: 5.38B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 30.68B CNY. Revenue FY2022 46.74B CNY. Revenue FY2023 53.53B CNY. Revenue FY2024 58.16B CNY. Revenue FY2025 73.44B CNY. Operating income FY2021 −1.4B CNY. Operating income FY2022 −145.12M CNY. Operating income FY2023 700.71M CNY. Operating income FY2024 1.16B CNY. Operating income FY2025 3.8B CNY. Net income FY2021 −1.07B CNY. Net income FY2022 380.11M CNY. Net income FY2023 2.14B CNY. Net income FY2024 4.16B CNY. Net income FY2025 5.38B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue73.44B CNY58.16B CNY53.53B CNY46.74B CNY30.68B CNY
Cost of goods sold55.24B CNY44.85B CNY41.66B CNY36.84B CNY23.48B CNY
Gross profit18.2B CNY13.31B CNY11.87B CNY9.89B CNY7.2B CNY
Research and development1.63B CNY1.33B CNY1.23B CNY1.07B CNY892.91M CNY
Selling, general, and administrative5.01B CNY4.47B CNY4.65B CNY4.35B CNY4.67B CNY
Operating expenses14.4B CNY12.15B CNY11.16B CNY10.05B CNY8.55B CNY
Interest income1.54B CNY1.96B CNY1.95B CNY864.27M CNY457.57M CNY
Interest expense11.1M CNY8.19M CNY9.49M CNY9.1M CNY6M CNY
Depreciation and amortization177.31M CNY151.95M CNY227.46M CNY140.68M CNY63.17M CNY
Operating income3.8B CNY1.16B CNY700.71M CNY−145.12M CNY−1.4B CNY
Net income5.38B CNY4.16B CNY2.14B CNY380.11M CNY−1.07B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
30%
3 beats, 7 misses, 0 met estimates
Average EPS surprise
-61.92%
10 comparable reports
Latest EPS result
1.24
Estimate 1.35 · Miss by 8.15%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.421.070.710.35Q2 '23BeatQ1 '24BeatQ3 '24MissQ1 '25BeatQ3 '25MissQ1 '26No estimateQ3 '26MissQ1 '27Estimate
Q2 2023, reported Jun 30, 2023: actual 0.534, estimate 0.416, surprise +28.33%, Beat. Q1 2024, reported Mar 20, 2024: actual 0.594, estimate 0.484, surprise +22.70%, Beat. Q3 2024, reported Aug 15, 2024: actual 0.697, estimate 0.707, surprise -1.41%, Miss. Q1 2025, reported Mar 5, 2025: actual 0.724, estimate 0.67, surprise +8.06%, Beat. Q3 2025, reported Aug 14, 2025: actual 0.885, estimate 1.09, surprise -18.81%, Miss. Q1 2026, reported Mar 5, 2026: actual 1.04, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual 1.24, estimate 1.35, surprise -8.15%, Miss. Q1 2027, reported Mar 29, 2027: actual —, estimate 1.12, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates54.62B45.2B35.79B26.37BQ2 '23MissQ1 '24BeatQ3 '24MissQ1 '25BeatQ3 '25BeatQ1 '26BeatQ3 '26MissQ1 '27Estimate
Q2 2023, reported Jun 30, 2023: actual 29.32B HKD, estimate 30.01B HKD, surprise -2.31%, Miss. Q1 2024, reported Mar 20, 2024: actual 29.07B HKD, estimate 28.47B HKD, surprise +2.09%, Beat. Q3 2024, reported Aug 15, 2024: actual 30.44B HKD, estimate 31.47B HKD, surprise -3.28%, Miss. Q1 2025, reported Mar 5, 2025: actual 31.72B HKD, estimate 31.5B HKD, surprise +0.69%, Beat. Q3 2025, reported Aug 14, 2025: actual 38.61B HKD, estimate 37.03B HKD, surprise +4.26%, Beat. Q1 2026, reported Mar 5, 2026: actual 42.61B HKD, estimate 41.6B HKD, surprise +2.43%, Beat. Q3 2026, reported Aug 13, 2026: actual 47.22B HKD, estimate 47.66B HKD, surprise -0.93%, Miss. Q1 2027, reported Mar 29, 2027: actual —, estimate 52.52B HKD, surprise —, Comparison unavailable.

6618.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

Continue in GoAI

Research 6618.HK

research.disclaimer